If further validated, due to the simplicity and cost-effectiveness, immunohistochemical testing of PLZF expression in PCa will have a significant impact and be of clinical utility in the management and personalized care of PCa patients in daily practice. This evidence concerns the gene ZBTB16 and posterior cortical atrophy.